The importance of prophylactic management of chemotherapy-induced neutropenia.
The development of colony-stimulating factors (CSFs) has provided clinicians with a valuable tool for proactive management of chemotherapy-induced neutropenia. However, clinicians are also presented with the challenge of appropriately targeting this treatment to patients at serious risk of neutropenic complications, while maintaining an economic approach to prescribing. This article discusses the seriousness of chemotherapy-induced neutropenia and reviews current approaches to the management of this condition. Febrile neutropenia risk models, new therapy options and international guidelines for the use of CSFs are also discussed.
Repetto
Lazzaro
L
Istituto Nazionale di Riposo e Cura per Anziani, Rome, Italy. l.repetto@inrca.it
Accettura
Caterina
C
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control; D003115:Colony-Stimulating Factors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D009181:Mycoses / Q000209:etiology / Q000517:prevention & control; D009503:Neutropenia / Q000139:chemically induced* / Q000191:economics / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D018570:Risk Assessment; D012307:Risk Factors
D000970:Antineoplastic Agents; D003115:Colony-Stimulating Factors